Arkuda Therapeutics Closes $44M Series A Financing to Advance Novel Medicines Targeting Progranulin and Lysosomal Biology to Treat Neurodegenerative Diseases

from Venture Capital Access Online: Latest Venture Capital and Private Equity News https://ift.tt/2ClXM7B
via IFTTT